Cargando…

Ifosfamide nephrotoxicity in adult patients

BACKGROUND: Ifosfamide, a widely prescribed antineoplasic agent, is frequently associated with kidney dysfunction. Its nephrotoxicity is well documented in children, but data are lacking in adult patients. METHODS: The aim of this retrospective study was to describe the clinical, biological and hist...

Descripción completa

Detalles Bibliográficos
Autores principales: Ensergueix, Gaël, Pallet, Nicolas, Joly, Dominique, Levi, Charlène, Chauvet, Sophie, Trivin, Claire, Augusto, Jean-Francois, Boudet, Rémi, Aboudagga, Hail, Touchard, Guy, Nochy, Dominique, Essig, Marie, Thervet, Eric, Lazareth, Hélène, Karras, Alexandre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467602/
https://www.ncbi.nlm.nih.gov/pubmed/32897279
http://dx.doi.org/10.1093/ckj/sfz183
_version_ 1783578048522616832
author Ensergueix, Gaël
Pallet, Nicolas
Joly, Dominique
Levi, Charlène
Chauvet, Sophie
Trivin, Claire
Augusto, Jean-Francois
Boudet, Rémi
Aboudagga, Hail
Touchard, Guy
Nochy, Dominique
Essig, Marie
Thervet, Eric
Lazareth, Hélène
Karras, Alexandre
author_facet Ensergueix, Gaël
Pallet, Nicolas
Joly, Dominique
Levi, Charlène
Chauvet, Sophie
Trivin, Claire
Augusto, Jean-Francois
Boudet, Rémi
Aboudagga, Hail
Touchard, Guy
Nochy, Dominique
Essig, Marie
Thervet, Eric
Lazareth, Hélène
Karras, Alexandre
author_sort Ensergueix, Gaël
collection PubMed
description BACKGROUND: Ifosfamide, a widely prescribed antineoplasic agent, is frequently associated with kidney dysfunction. Its nephrotoxicity is well documented in children, but data are lacking in adult patients. METHODS: The aim of this retrospective study was to describe the clinical, biological and histological characteristics of ifosfamide nephrotoxicity. RESULTS: We report 34 patients (median age: 41 years) admitted in six French nephrology departments for kidney failure and/or tubular dysfunction. Fifteen patients (44.1%) received cisplatin as part of their chemotherapy. In 6 patients (17.7%), ifosfamide nephrotoxicity was revealed by a proximal tubular dysfunction (PTD), in 5 patients (14.4%) by an acute kidney injury (AKI), in 6 patients (17.7%) by a chronic kidney disease (CKD) and in 17 patients (49.7%) by an association of PTD and AKI. Fourteen renal biopsies (41.2%) were performed and revealed acute tubular necrosis (85.7%), vacuolation (78.6%) and nuclear atypias (71.4%) of renal epithelial cells, interstitial inflammation (71.4%) and fibrosis (57.1%). Electron microscopy showed mitochondrial enlargement and dysmorphic changes suggestive of mitochondrial toxicity. Ten patients (29.4%) progressed to Stage 5 CKD, six (17.6%) required haemodialysis and six patients died during a median follow-up period of 31 months. Risk factors for Stage 5 CKD were age and cisplatin co-administration.
format Online
Article
Text
id pubmed-7467602
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-74676022020-09-03 Ifosfamide nephrotoxicity in adult patients Ensergueix, Gaël Pallet, Nicolas Joly, Dominique Levi, Charlène Chauvet, Sophie Trivin, Claire Augusto, Jean-Francois Boudet, Rémi Aboudagga, Hail Touchard, Guy Nochy, Dominique Essig, Marie Thervet, Eric Lazareth, Hélène Karras, Alexandre Clin Kidney J Original Articles BACKGROUND: Ifosfamide, a widely prescribed antineoplasic agent, is frequently associated with kidney dysfunction. Its nephrotoxicity is well documented in children, but data are lacking in adult patients. METHODS: The aim of this retrospective study was to describe the clinical, biological and histological characteristics of ifosfamide nephrotoxicity. RESULTS: We report 34 patients (median age: 41 years) admitted in six French nephrology departments for kidney failure and/or tubular dysfunction. Fifteen patients (44.1%) received cisplatin as part of their chemotherapy. In 6 patients (17.7%), ifosfamide nephrotoxicity was revealed by a proximal tubular dysfunction (PTD), in 5 patients (14.4%) by an acute kidney injury (AKI), in 6 patients (17.7%) by a chronic kidney disease (CKD) and in 17 patients (49.7%) by an association of PTD and AKI. Fourteen renal biopsies (41.2%) were performed and revealed acute tubular necrosis (85.7%), vacuolation (78.6%) and nuclear atypias (71.4%) of renal epithelial cells, interstitial inflammation (71.4%) and fibrosis (57.1%). Electron microscopy showed mitochondrial enlargement and dysmorphic changes suggestive of mitochondrial toxicity. Ten patients (29.4%) progressed to Stage 5 CKD, six (17.6%) required haemodialysis and six patients died during a median follow-up period of 31 months. Risk factors for Stage 5 CKD were age and cisplatin co-administration. Oxford University Press 2019-12-31 /pmc/articles/PMC7467602/ /pubmed/32897279 http://dx.doi.org/10.1093/ckj/sfz183 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Articles
Ensergueix, Gaël
Pallet, Nicolas
Joly, Dominique
Levi, Charlène
Chauvet, Sophie
Trivin, Claire
Augusto, Jean-Francois
Boudet, Rémi
Aboudagga, Hail
Touchard, Guy
Nochy, Dominique
Essig, Marie
Thervet, Eric
Lazareth, Hélène
Karras, Alexandre
Ifosfamide nephrotoxicity in adult patients
title Ifosfamide nephrotoxicity in adult patients
title_full Ifosfamide nephrotoxicity in adult patients
title_fullStr Ifosfamide nephrotoxicity in adult patients
title_full_unstemmed Ifosfamide nephrotoxicity in adult patients
title_short Ifosfamide nephrotoxicity in adult patients
title_sort ifosfamide nephrotoxicity in adult patients
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467602/
https://www.ncbi.nlm.nih.gov/pubmed/32897279
http://dx.doi.org/10.1093/ckj/sfz183
work_keys_str_mv AT ensergueixgael ifosfamidenephrotoxicityinadultpatients
AT palletnicolas ifosfamidenephrotoxicityinadultpatients
AT jolydominique ifosfamidenephrotoxicityinadultpatients
AT levicharlene ifosfamidenephrotoxicityinadultpatients
AT chauvetsophie ifosfamidenephrotoxicityinadultpatients
AT trivinclaire ifosfamidenephrotoxicityinadultpatients
AT augustojeanfrancois ifosfamidenephrotoxicityinadultpatients
AT boudetremi ifosfamidenephrotoxicityinadultpatients
AT aboudaggahail ifosfamidenephrotoxicityinadultpatients
AT touchardguy ifosfamidenephrotoxicityinadultpatients
AT nochydominique ifosfamidenephrotoxicityinadultpatients
AT essigmarie ifosfamidenephrotoxicityinadultpatients
AT therveteric ifosfamidenephrotoxicityinadultpatients
AT lazarethhelene ifosfamidenephrotoxicityinadultpatients
AT karrasalexandre ifosfamidenephrotoxicityinadultpatients